Blinatumomab for treating acute lymphoblastic leukemia

Bibliography

• MHNelson, CMPaulos. Novel immunotherapies for hematologic malignancies. Immunol Rev 2015;263:90-105
   PubMed Web of Science ®Google Scholar
• SLMaude, NFrey, PAShaw, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17
   PubMed Web of Science ®Google Scholar
• MLDavila, IRiviere, XWang, et al. Efficacy and toxicity management of 19-28z CART cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6(224):224ra25
   PubMed Web of Science ®Google Scholar
• DWLee, JNKochenderfer, MStetler-Stevenson, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385(9967):517-28
   PubMed Web of Science ®Google Scholar
• ZZimmerman, TManiar, DNagorsen. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy. Int Immunol 2015;27(1):31-7
   PubMed Web of Science ®Google Scholar
• DNagorsen, PABaeuerle. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011;317:1255-60
   PubMed Web of Science ®Google Scholar
• XThomas. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol 2015;16(1):6-7
   PubMed Web of Science ®Google Scholar
• RBassan. Toward victory in adult ALL: blinatumomab joins in. Blood 2012;120:5094-5
   PubMed Web of Science ®Google Scholar
• Cancer Statistics US; Working Group. United States Cancer Statistics: 1999–2010 Incidence and Mortality Web-based Report. Department of Health and Human Services. Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta, GA; 2013. Available from: http://www.cdc.gov/uscs[ Last accessed 29 December 2014]
   Google Scholar
• KNguyen, MDevidas, SCCheng, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia 2008;22:2142-50
   PubMed Web of Science ®Google Scholar
• AKFielding, SMRichards, RChopra, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944-50
   PubMed Web of Science ®Google Scholar
• NGökbuget, DStanze, JBeck, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-41
   PubMed Web of Science ®Google Scholar
• HMKantarjian, DThomas, FRavandi, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-74
   PubMed Web of Science ®Google Scholar
• SO’Brien, DThomas, FRavandi, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113:3186-91
   PubMed Web of Science ®Google Scholar
• AOriol, SVives, JMHernandez-Rivas, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-96
   PubMed Web of Science ®Google Scholar
• ETavernier, JMBoiron, FHuguet, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-14
   PubMed Web of Science ®Google Scholar
• SRaponi, MSDe Propris, SIntoppa, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098-107
   PubMed Web of Science ®Google Scholar
• JAi, AAdvani. Current status of antibody therapy in ALL. Br J Haematol 2015;168(4):471-80
   PubMedGoogle Scholar
• LMHoffman, LGore. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE(®) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 2014;4:63
   PubMedGoogle Scholar
• MSMathisen, HMKantarjian, EJJabbour. Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs 2014;19:37-50
   PubMed Web of Science ®Google Scholar
• DHoelzer. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol 2013;25:701-6
   PubMedGoogle Scholar
• MRLitzow. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book 2013;294-9
   PubMedGoogle Scholar
• SAParikh, MRLitzow. Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. Future Oncol 2014;10:2201-12
   PubMedGoogle Scholar
• DDouer. Will novel agents for ALL finally change the natural history? Best Pract Res Clin Haematol 2014;27:247-58
   PubMedGoogle Scholar
• HKantarjian, DThomas, JJorgensen, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-36
   PubMed Web of Science ®Google Scholar
• CBrandl, CHaas, Sd’Argouges, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-63
   PubMed Web of Science ®Google Scholar
• RBargou, ELeo, GZugmaier, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
   PubMed Web of Science ®Google Scholar
• CAPortell, CMWenzell, ASAdvani. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013;5(Suppl 1):5-11
   PubMedGoogle Scholar
• CRathi, BMeibohm. Clinical pharmacology of bispecific antibody constructs. J Clin Pharmacol 2014;10.1002/jcph.446
   Google Scholar
• GZugmaier, MSTopp, SAlekar, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:244
   PubMed Web of Science ®Google Scholar
• MKlinger, CBrandl, GZugmaier, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-33
   PubMed Web of Science ®Google Scholar
• DTTeachey, SRRheingold, SLMaude, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154-7
   PubMed Web of Science ®Google Scholar
• PSchlegel, PLang, GZugmaier, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014;99:1212-19
   PubMed Web of Science ®Google Scholar
• RHandgretinger, GZugmaier, GHenze, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-4
   PubMed Web of Science ®Google Scholar
• Avon Stackelberg, FLocatelli, GZugmaier, et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment [abstract 2292]. 56th ASH Meeting and Exposition, San Francisco, CA; December 6-9, 2014; 2014
   Google Scholar
• BWu, YHijazi, AWolf, et al. Pharmacokinetics (PK) of blinatumomab and its clinical implications. J Clin Oncol 2013;31(Suppl):abstract 3048
   Google Scholar
• MSTopp, PKufer, NGökbuget, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8
   PubMed Web of Science ®Google Scholar
• MSTopp, NGökbuget, GZugmaier, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-7
   PubMed Web of Science ®Google Scholar
• ASAdvani. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2011;9:776-7
   PubMedGoogle Scholar
• MSTopp, NGökbuget, GZugmaier, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32:4134-40
   PubMed Web of Science ®Google Scholar
• MSTopp, NGökbuget, ASStein, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16(1):57-99
   PubMed Web of Science ®Google Scholar
• NGoekbuget, HMKantarjian, MBrüggemann, et al. An evaluation of molecular response in a phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) receiving treatment with the BiTE® antibody construct blinatumomab [abstract 3704]. 56th ASH Meeting and Exposition, San Francisco, CA; December 6-9, 2014; 2014
   Google Scholar
• NGoekbuget, HDombret, MBonifacio, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific t-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL) [abstract 379]. 56th ASH Meeting and Exposition, San Francisco, CA; December 6-9, 2014; 2014
   Google Scholar
• LGore, FLocatelli, GZugmaier, et al. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia [abstract 3703]. 56th ASH Meeting and Exposition, San Francisco, CA; December 6-9, 2014; 2014
   Google Scholar
• DMBarrett, DTTeachey, SAGrupp. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014;26:43-9
   PubMed Web of Science ®Google Scholar
• FRAppelbaum, DRosenblum, RJArceci, et al. Endpoints to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007;109:1810-16
   PubMed Web of Science ®Google Scholar